EBV counteracts IL-21-induced apoptosis in an EBV-positive diffuse large B-cell lymphoma cell line

被引:15
作者
Wu, Liang [1 ]
Ehlin-Henriksson, Barbro [1 ]
Zhu, Hong [2 ]
Ernberg, Ingemar [1 ]
Klein, George [1 ]
机构
[1] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, S-17177 Stockholm, Sweden
[2] Cent S Univ, Dept Oncol, Xiangya Hosp, Changsha, Hunan, Peoples R China
关键词
EpsteinBarr virus; IL-21; diffuse large B-cell lymphoma; proliferation; EPSTEIN-BARR-VIRUS; NON-HODGKINS-LYMPHOMA; NF-KAPPA-B; LYMPHOPROLIFERATIVE DISORDERS; SIGNALING PATHWAY; CANCER-THERAPY; INTERLEUKIN-21; ACTIVATION; BIOLOGY; IL-21;
D O I
10.1002/ijc.28067
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previously, interleukin (IL)-21 has been found to induce apoptosis by activating the signal transducer and activator of transcription 3 (STAT3) and concomitant upregulation of c-Myc in diffuse large B-cell lymphoma (DLBCL) lines with unknown EpsteinBarr virus (EBV) status. Here, as a first approach toward the characterization of the role of EBV in DLCBL, the EBV gene expression and the IL-21 sensitivity of the EBV-positive DLBCL line, Farage, have been examined. It was found that, surprisingly, despite c-Myc upregulation, IL-21 induced cell proliferation rather than apoptosis in Farage. Expression of a dominant-negative EBNA1 mutant and the consecutive downregulation of EBV gene expression antagonized the IL-21-induced proliferation of Farage and increased apoptosis. These findings reveal a previously unknown role of EBV in DLBCL that is of possible relevance for the current attempt to use IL-21 in therapy.
引用
收藏
页码:766 / 770
页数:5
相关论文
共 25 条
  • [1] Interleukin-21: biology and application to cancer therapy
    Andorsky, David J.
    Timmerman, John M.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (09) : 1295 - 1307
  • [2] [Anonymous], 1997, BLOOD
  • [3] Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-κB2 to p52 via an IKKγ/NEMO-independent signalling pathway
    Eliopoulos, AG
    Caamano, JH
    Flavell, J
    Reynolds, GM
    Murray, PG
    Poyet, JL
    Young, LS
    [J]. ONCOGENE, 2003, 22 (48) : 7557 - 7569
  • [4] HARRIS NL, 1994, BLOOD, V84, P1361
  • [5] Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma
    Hashmi, Mehmood H.
    Van Veldhuizen, Peter J.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (05) : 807 - 817
  • [6] HUEN DS, 1995, ONCOGENE, V10, P549
  • [7] Jaffe E.S., 2009, American Society of Hematology. Education Program, P523
  • [8] Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or bim-dependent apoptosis
    Jin, HL
    Carrio, R
    Yu, AX
    Malek, TR
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 173 (01) : 657 - 665
  • [9] Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions
    Klein, E.
    Kis, L. L.
    Klein, G.
    [J]. ONCOGENE, 2007, 26 (09) : 1297 - 1305
  • [10] The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma:: Comparison between EBV+ and EBV- cases in Japanese population
    Kuze, T
    Nakamura, N
    Hashimoto, Y
    Sasaki, Y
    Abe, M
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 2000, 91 (12): : 1233 - 1240